BioLineRx 2025: the loss nearly disappeared, but the funding test is only starting

Company Introduction

BioLineRx at the end of 2025 is no longer a small commercial-stage biotech trying to build its own U.S. sales engine. It now looks much more like a lean development platform trying to fund itself through two motixafortide licensing agreements while adding a new option through GLIX1. That distinction matters because a reader who stops at the net loss line may come away with the impression that the company is close to breakeven. That would be the wrong read.

What is actually working now is clear enough. Cash burn fell sharply. Operating cash outflow improved to negative $8.1 million from negative $43.9 million in 2024. Selling and marketing expense dropped to zero after the shutdown of BioLineRx’s own U.S. commercial operation. BlackRock debt fell to $8.9 million from $13.4 million, and year-end cash, cash equivalents and short-term bank deposits stood at $20.9 million. The company also entered 2026 with a much smaller operating footprint of 24 full-time and 4 part-time employees.

What is still not clean is just as important. First, revenue itself collapsed. In 2025 the company recorded only $1.18 million of revenue, all of it royalties from Ayrmid, versus $28.9 million in 2024. Second, part of the apparent improvement in profitability came from below the operating line: an $8.6 million gain from the fair-value remeasurement of warrants, plus a $0.8 million reversal of a doubtful-account provision after a delayed Gloria payment was collected. Third, GLIX1 created a real strategic option, but it also created a real funding obligation: BioLineRx committed to invest $5 million into Tetragon within 36 months, and by year-end 2025 only $1.2 million had been funded.

There is also a practical screen issue here. The last trading day in the prepared market snapshot showed turnover of only about NIS 47 thousand, while short interest was negligible. In other words, if the market continues to see BioLineRx primarily as a funding story rather than an execution story, it is likely to express that view through weak liquidity, dilution risk and financing sensitivity, not through an aggressive short setup.

The right way to read BioLineRx now is as a three-part economic structure:

That chart captures the core shift. In 2024 there was still a blend of upfronts, milestones and direct APHEXDA sales in the U.S. By 2025 almost all that was left was one royalty stream. BioLineRx is no longer a launch story. It is a development story with a royalty base.

That concentration matters. In 2025 there was no meaningful contribution from Asia, and revenue effectively came from one market through one partner. The 2026 and 2027 story will therefore be determined less by how attractive the scientific narrative sounds and more by whether one of the two partners can actually turn licensed rights into cash.

Events And Triggers

The move to a licensing model is complete, but the top line paid the price

Trigger one: 2025 is the first year that mostly reflects BioLineRx after the APHEXDA handoff. That instantly took selling and marketing expense from $23.6 million to zero and materially improved operating cash burn. But it also exposed the other side of the trade. Without direct product sales and without upfront recognition, the company was left with only $1.18 million of revenue. This is not presentation noise. It is a business-model reset.

Trigger two: GLIX1 moved from strategic promise to an asset that now has to be judged against a real timeline. The IND was cleared by the FDA in August 2025, Phase 1/2 initiation in GBM and other cancers is expected in Q1 2026, Phase 1 data is anticipated in H1 2027 and Phase 2 data in H1 2028. That gives the company a new narrative, but not yet a new cash engine.

Trigger three: motixafortide has become a two-track story. On the positive side, the China SCM bridging study began toward the end of 2025, and the company points to a first patient dose at year-end. On the more troubling side, the randomized PDAC study in China under Gloria is not advancing on schedule, and management explicitly says it is unclear when it will start, if at all. Anyone treating the Gloria deal as broad monetization progress has to confront the fact that the Asia leg is currently moving only in part.

Trigger four: the January 2025 financing bought time, but it also expanded the equity base. The registered direct offering included 858,303 ADSs plus pre-funded warrants for another 391,697 ADSs, raised $10 million gross and $8.9 million net, and added a new warrant layer. As of March 8, 2026 the company still had roughly $4.5 million of near-term capacity left under the ATM program, but that is not a large cushion for a biotech that is still advancing new development work.

That chart makes a point the market often underweights when cash looks more comfortable: part of the survival improvement was purchased through heavy dilution. The share count almost doubled in 2025 alone.

GLIX1 creates a new option, but not for free

At first glance, the Hemispherian transaction looks like a smart way to add a clinical-stage asset without paying the full price in cash upfront. That is partly true. BioLineRx received 40% of Tetragon, can move up to 70% ownership if it invests above the $5 million threshold, and holds the deciding vote in deadlocks, which gives it accounting control. But this is exactly where created value has to be separated from accessible value.

The company recorded a $6.0 million intangible asset related to GLIX1 and recorded minority interest on the other side. That strengthens the balance-sheet optics, but it does not add cash. On top of that, Tetragon pays Hemispherian a monthly advisory fee of $80 thousand for up to 24 months or until the collaboration ends, and BioLineRx still has to fund the remaining $3.8 million of the threshold amount to avoid risking part of its stake. GLIX1 is therefore not just a new clinical option. It is also a measurable future funding commitment.

Efficiency, Profitability And Competition

The main story of 2025 is not growth. It is a reset of the expense base. That matters, but it has to be read correctly: BioLineRx did not build a new profitable engine. It replaced an expensive business model with a leaner one. The result looks good in the net-loss line, but the quality of that improvement is much less impressive once the pieces are separated.

The sharpest drop is obviously in selling and marketing, which disappeared after APHEXDA was moved to Ayrmid. That makes cash burn easier to manage, but it does not in itself prove competitive strength. If anything, it shows that BioLineRx gave up on being a stand-alone commercial player and shifted to a structure where an outside partner is expected to do the selling.

R&D fell much less, from $9.15 million to $8.09 million. That is a key read. The company is not simply sitting on royalty income. It is still funding development, and the fall in motixafortide-related expense was partly offset by the start of GLIX1 work. In biotech terms, that is a double signal: there is a fresh asset in the pipeline, but the expense base is still well above what a tiny royalty stream can comfortably support.

G&A fell by 50.3%, but here too the clean number overstates the recurring improvement. In 2025 BioLineRx recorded an $0.8 million reversal of a doubtful-account provision after collecting a delayed Gloria payment. So part of the apparent G&A improvement is not repeatable efficiency but the reversal of a prior problem. If the 2024 provision and the 2025 reversal are normalized out, G&A still declines, but by a much more moderate amount.

This may be the most important chart in the file. Operating loss improved by nearly 50% to $10.3 million, but that is still a very large loss against only $1.2 million of revenue. Net loss fell to $2.0 million mainly because the company booked $8.1 million of non-operating income, mostly from changes in warrant fair value. That is volatile accounting income, not proof that the business itself is close to profitability.

On competition, BioLineRx itself is now much less exposed on the direct commercial side. The competitive fight around APHEXDA versus Mozobil and generic versions largely sits with Ayrmid and Gloria. So the real competitive question for investors is no longer whether BioLineRx can sell well on its own. It is whether its partners can create uptake that translates into meaningful cash for BioLineRx.

Cash Flow, Debt And Capital Structure

Cash flow: much calmer, still not self-funding

In 2025 BioLineRx used $8.1 million of cash in operating activities. That is a dramatic improvement versus 2024, but it is still cash burn, not cash generation. It is important to define the frame here. For BioLineRx the right frame is all-in cash flexibility, because the real question is not what the business might produce before other claims, but how much actual room remains after real cash uses.

On that basis, the picture is straightforward: negative $8.1 million from operations, negative $4.5 million of loan repayments, and negative $0.5 million of lease repayments. Against that, the company brought in $13.9 million of net proceeds from equity, pre-funded instruments and warrants. Without capital markets access, 2025 would have looked much less comfortable.

Year-end liquidity does look better: $20.9 million of cash, cash equivalents and short-term deposits against $8.9 million of BlackRock debt. On a rough balance-sheet view that is about $11.9 million of liquid resources above the financial debt balance. But that is not the end of the story, because that liquidity still has to support continued R&D, lease payments and Tetragon funding.

Debt: smaller, but still with teeth

The BlackRock debt problem improved, but it did not disappear. The amendment at the end of 2024 removed the revenue-share component on U.S. APHEXDA sales, lowered the minimum cash covenant from $10 million to $4 million, and spread the remaining principal and interest through December 1, 2027. On the other hand, 10% of any future milestone payments received from licensing agreements until that date will still be used to repay loan principal.

That point matters a lot. If Ayrmid or Gloria begin to generate milestones, not every dollar of that upside will flow to common shareholders or even remain in the cash balance. Part of it is effectively pre-claimed by the lender. So the company’s ability to capture value from partner success is weaker than a superficial reading of the headline milestone figures might suggest.

The loan also remains secured on substantially all company assets. So the funding pressure no longer looks like an immediate cliff, but it is still relevant if royalties disappoint or GLIX1 requires more capital sooner than expected.

Capital structure: the balance sheet is stronger, but not all of it is cash

Total equity rose to $23.3 million from $13.5 million at the end of 2024. That sounds like a major strengthening. In practice, two things matter. First, equity attributable to owners is $18.2 million, not the full $23.3 million, because $5.1 million sits in non-controlling interest. Second, part of the improvement reflects the recognition of a $6.0 million intangible asset related to GLIX1 against minority interest. That is a legitimate accounting step, but it is not the same thing as fresh cash.

Investors therefore should not read the BioLineRx balance sheet as the balance sheet of a company that suddenly got rich. It is the balance sheet of a company that bought time and bought a new option, at the price of dilution and future commitments.

Outlook

Before getting into the timeline, here are the four findings that matter most for 2026:

• The company did not reach breakeven. It simply shifted to a model that became leaner much faster than revenue became durable.
• The cash picture looks safer largely because 2025 included new financing and deferred pressure, not because royalties have already built a self-funding base.
• GLIX1 is a real upside option, but it comes with a clear and measurable funding obligation.
• The gap between Ayrmid and Gloria is likely to be decisive: one partner is already paying royalties, the other is still slow on PDAC.

2026 looks like a bridge year, not a breakout year

Management does not provide a classic numeric guidance framework here, but the filing still gives enough anchors to judge the kind of year ahead. This looks like a bridge year. Not because there is nothing to measure, but because the company still sits between two identities: behind it is an expensive direct-commercialization model that is gone, and ahead of it is a royalty-plus-development model that has not yet proven it can fund itself.

For GLIX1, the first milestone is Phase 1/2 initiation in Q1 2026. After that, the real tests are operational: site activation, enrollment pace and budget control inside Tetragon. Any delay here would not only hurt the scientific narrative, it would also hurt confidence that the Hemispherian transaction can be translated into a real development path.

For motixafortide outside Asia, the question is whether Ayrmid royalties can start rising to a level that is actually visible against an expense base still running in the high single-digit millions of dollars. Right now the answer is no. The $1.2 million of 2025 royalties is a starting point, not a funding base. In Asia, the SCM track moved forward late in 2025, but the PDAC track remains stalled. As long as that is true, it is hard to assign the Gloria deal its full theoretical value.

What the market will test over the next 2 to 4 quarters

The first test is simple: does 2026 preserve something close to the 2025 cash-burn profile, or do Tetragon funding and development activity push the burn back up. The second is qualitative: does GLIX1 actually enter the clinic on time. The third is commercial: does Ayrmid continue to build sales into rising royalties, rather than symbolic payments. The fourth is financial: can BioLineRx keep moving without another meaningful dilutive raise in the near term.

In market-reading terms, BioLineRx could look deceptively better simply because net loss is small and management says cash should last into H1 2027. But the real question the market has to answer is whether 2025 was mainly an accounting and cost clean-up after an expensive launch phase, or the start of a leaner model that can survive long enough to reach new clinical proof points without running straight back into dilution.

Risks

The first risk is funding and dilution. Management still includes a substantial-doubt going-concern warning even while saying current cash resources should fund the company into the first half of 2027. That is not a technical contradiction. It is a genuine warning sign: visibility improved, but the company still depends on realizing partnership cash flows and likely also on future access to capital markets.

The second risk is partner concentration. In 2025 all revenue came from the U.S., which in practice means Ayrmid. Gloria still matters strategically, but it is not currently delivering comparable economic contribution, and the China PDAC study remains delayed. That leaves BioLineRx with one active revenue source and one important but still under-delivering partner channel.

The third risk is that GLIX1 becomes an expense engine before it becomes a value engine. The $5 million Tetragon funding obligation, the $80 thousand monthly advisory fee, and the need to show real clinical progress already in 2026 create a classic biotech platform risk: the company adds an attractive option, but before that option is clinically validated, it is already consuming capital.

The fourth risk is bottom-line distortion. Warrant accounting creates major P&L volatility. In 2025 that helped, with an $8.6 million gain from fair-value changes. In another year it can move the other way. Any thesis built on the reported bottom line without separating the warrant layer is vulnerable to a serious analytical mistake.

Short interest is almost non-existent, and clearly below the sector average. That does not make the stock safe. It simply means the risk is being expressed through weak liquidity, dilution and execution pressure, not through an active short setup.

Conclusions

BioLineRx ended 2025 in a more stable place than where it started the year: the expense base is far leaner, cash burn fell sharply, and BlackRock debt came down. But this is still not a mature royalty company, and it is certainly not a biotech that has already funded its own next phase. The main bottleneck remains funding: how quickly royalties and future milestones can become clean cash, and whether that can happen before another major financing round.

Current thesis in one line: BioLineRx has moved from an expensive launch model to a leaner development-and-royalty structure with a new GLIX1 option, but the 2025 improvement mostly bought time rather than solved the business model.

What changed versus the old way of reading the company is straightforward. BioLineRx used to be judged as a company trying to build direct APHEXDA sales. It should now be judged as a small platform managing licensed rights, royalties and development programs, with heavy reliance on third-party execution.

The strongest counter-thesis is that this is exactly what the company needed to do: exit an expensive commercial effort, keep economic exposure to APHEXDA, add a differentiated new asset, and reach H1 2027 with enough time to wait for data and milestones. That is a serious argument. The problem is that it still requires several links in the chain to work at once, not just one.

What could change the market’s reading in the short to medium term? First, rising royalties from Ayrmid. Second, a clean GLIX1 clinical start. Third, any sign that Gloria is moving again on PDAC. On the other side, another near-term raise, GLIX1 delays or continued stagnation in China would pull the stock quickly back into a dilution story rather than an option story.

Why this matters is simple. BioLineRx is trying to move from a model that burned capital to sell, to a model that buys time in order to prove fresh clinical value. If that transition works, the structure will look much more coherent. If it fails, 2025 will mostly be remembered as the year the accounting loss shrank faster than the economic risk.

What has to happen in the next 2 to 4 quarters for the thesis to improve? GLIX1 needs to enter the clinic on time, cash burn has to stay controlled, Ayrmid royalties need to show an upward trend, and Gloria needs to show at least one meaningful sign of progress. What would weaken the read? A return to capital-markets dependence, slippage in GLIX1 timelines, or a continued reality in which only one partner is actually generating money.